Arthur J Caplan

Dr. Arthur J Caplan

orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 June 2017 in The American Journal of Bioethics
Verified
Journal Article
Closed access
PFPhoebe Friesen
Phoebe Friesen
LKLisa Kearns
Lisa Kearns
BRBarbara Redman
Barbara Redman
ACArthur J Caplan
Arthur J Caplan
This article reflects on the relevance and applicability of the Belmont Report nearly four decades after its original publication. In an exploration of criticisms that have been raised in response to the report and of significant changes that have occurred within the context of biomedical research, five primary themes arise. These themes include the increasingly vague boundary between research and practice, unique harms to communities that are not addressed by the principle of respect for persons, and how growing complexity and commodification in research have shed light on the importance of transparency. The repercussions of Belmont's emphasis on the protection of vulnerable populations is also explored, as is the relationship between the report's ethical principles and their applications. It is concluded that while the Belmont Report was an impressive response to the ethical issues of its day, the field of research ethics involving human subjects may have outgrown it.

5 December 2019 in Journal of Law and the Biosciences
Verified
Journal Article
Open access
PDF file
CCCarolyn Riley Chapman
Carolyn Riley Chapman
KMKripa Sanjay Mehta
Kripa Sanjay Mehta
BPBrendan Parent
Brendan Parent
ACArthur J Caplan
Arthur J Caplan
Genetic testing is becoming more widespread, and its capabilities and predictive power are growing. In this paper, we evaluate the ethical justifications for and strength of the US legal framework that aims to protect patients, research participants, and consumers from genetic discrimination in employment and health insurance settings in the context of advancing genetic technology. The Genetic Information Nondiscrimination Act (GINA) and other laws prohibit genetic and other health-related discrimination in the United States, but these laws have significant limitations, and some provisions are under threat. If accuracy and predictive power increase, specific instances of use of genetic information by employers may indeed become ethically justifiable; however, any changes to laws would need to be adopted cautiously, if at all, given that people have consented to genetic testing with the expectation that there would be no genetic discrimination in employment or health insurance settings. However, if our society values access to healthcare for both the healthy and the sick, we should uphold strict and broad prohibitions against genetic and health-related discrimination in the context of health insurance, including employer-based health insurance. This is an extremely important but often overlooked consideration in the current US debate on healthcare.

13 April 2017 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Open access
AEAyelet Evrony
Ayelet Evrony
ACArthur J Caplan
Arthur J Caplan
(2017). The overlooked dangers of anti-vaccination groups' social media presence. Human Vaccines & Immunotherapeutics: Vol. 13, No. 6, pp. 1475-1476.

1 June 2021 in Annals of Internal Medicine
Verified
Journal Article
Open access
BTBrit Trogen
Brit Trogen
ACArthur J Caplan
Arthur J Caplan
The authors of this commentary discuss the “Peltzman Effect,” a phenomenon in which individuals respond to safety measures with a compensatory increase in risky behavior, and how it relates to the ...

5 March 2019 in JAMA
Verified
Journal Article
Open access
PDF file
STShailin Thomas
Shailin Thomas
ACArthur J Caplan
Arthur J Caplan
This Viewpoint reviews unintended consequences of the 1983 Orphan Drug Act, which incentivized development of drugs for rare diseases, including abbreviated app

3 April 2015 in The American Journal of Bioethics
Verified
Journal Article
Closed access
ACArthur J Caplan
Arthur J Caplan
CPCarolyn Plunkett
Carolyn Plunkett
BLBruce Levin
Bruce Levin
There are competing ethical concerns when it comes to designing any clinical research study. Clinical trials of possible treatments for Ebola virus are no exception. If anything, the competing ethical concerns are exacerbated in trying to find answers to a deadly, rapidly spreading, infectious disease. The primary goal of current research is to identify experimental therapies that can cure Ebola or cure it with reasonable probability in infected individuals. Pursuit of that goal must be methodologically sound, practical and consistent with prevailing norms governing human subjects research. Some maintain that only randomized controlled trials (RCTs) with a placebo or standard-of-care arm can meet these conditions. We maintain that there are alternative trial designs that can do so as well and that sometimes these are preferable to RCTs.